(-0.03%) 5 476.75 points
(-0.04%) 38 803 points
(0.01%) 19 923 points
(0.29%) $80.56
(1.11%) $2.82
(0.12%) $2 331.70
(-0.36%) $29.29
(-0.13%) $969.60
(0.02%) $0.932
(-0.12%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies...
Stats | |
---|---|
Šios dienos apimtis | 573 345 |
Vidutinė apimtis | 232 503 |
Rinkos kapitalizacija | 120.72M |
EPS | $-0.120 ( Q1 | 2024-05-07 ) |
Kita pelno data | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-3.78 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-13 | Grais Linda | Buy | 15 000 | Stock Option (Right to Buy) |
2024-06-13 | Clark Ian T | Buy | 15 000 | Stock Option (Right to Buy) |
2024-06-13 | Morrison Scott W | Buy | 15 000 | Stock Option (Right to Buy) |
2024-06-13 | Gould Terry P | Buy | 15 000 | Stock Option (Right to Buy) |
2024-06-13 | Thompson Peter A. | Buy | 15 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
93.22 |
Last 98 transactions |
Buy: 11 774 084 | Sell: 7 521 304 |
Tūris Koreliacija
Corvus Pharmaceuticals Koreliacija
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Corvus Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Corvus Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-151 000 (0.00 %) |
EPS: | $-0.560 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-151 000 (0.00 %) |
EPS: | $-0.560 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-367 000 (0.00 %) |
EPS: | $-1.080 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.030 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.